tetano
Editor, Senior Moderator
Hum Immunol
. 2022 Aug 8;S0198-8859(22)00158-6.
doi: 10.1016/j.humimm.2022.08.004. Online ahead of print.
Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Alessio Alesci[SUP] 1 [/SUP], Marco Gitto[SUP] 2 [/SUP], Magdalena Kotańska[SUP] 3 [/SUP], Patrizia Lo Cascio[SUP] 4 [/SUP], Anthea Miller[SUP] 5 [/SUP], Noemi Nicosia[SUP] 6 [/SUP], Angelo Fumia[SUP] 7 [/SUP], Simona Pergolizzi[SUP] 8 [/SUP]
Affiliations
Abstract
In December 2019, a new single-stranded RNA coronavirus, SARS-CoV-2, appeared in China and quickly spread around the world leading to a pandemic. Infection with SARS-CoV-2 generates symptoms ranging from asymptomatic to severe, occasionally requiring hospitalization in intensive care units, and, in more severe cases, leading to death. Scientists and researchers around the world have made a real race against time to develop various vaccines to slow down and stop the spread of the virus. In addition to conventional viral vector vaccines, new generation mRNA vaccines, BNT152b2 (Comirnaty) and mRNA-1273 (Spikevax), have been developed respectively by Pfizer/BioNTech and Moderna. These vaccines act on immune cells to induce an immune response with the production of specific antibodies against Spike protein of SARS-CoV-2, and to stimulate the differentiation of T and B memory cells. The objective of this review is to provide a detailed picture of the validity of these new vaccines and the safety of vaccination. Not only was the immunogenic effect of mRNA vaccines evaluated, but also the psychosocial impact they had on the population. The data collected show that this type of vaccine can also be an excellent candidate for future treatment and eradication of possible new pathologies with viral and non-viral etiology.
Keywords: Comirnaty; Immunity; SARS-CoV-2; Spikevax; Vaccination.
. 2022 Aug 8;S0198-8859(22)00158-6.
doi: 10.1016/j.humimm.2022.08.004. Online ahead of print.
Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
Alessio Alesci[SUP] 1 [/SUP], Marco Gitto[SUP] 2 [/SUP], Magdalena Kotańska[SUP] 3 [/SUP], Patrizia Lo Cascio[SUP] 4 [/SUP], Anthea Miller[SUP] 5 [/SUP], Noemi Nicosia[SUP] 6 [/SUP], Angelo Fumia[SUP] 7 [/SUP], Simona Pergolizzi[SUP] 8 [/SUP]
Affiliations
- PMID: 35963787
- PMCID: PMC9359511
- DOI: 10.1016/j.humimm.2022.08.004
Abstract
In December 2019, a new single-stranded RNA coronavirus, SARS-CoV-2, appeared in China and quickly spread around the world leading to a pandemic. Infection with SARS-CoV-2 generates symptoms ranging from asymptomatic to severe, occasionally requiring hospitalization in intensive care units, and, in more severe cases, leading to death. Scientists and researchers around the world have made a real race against time to develop various vaccines to slow down and stop the spread of the virus. In addition to conventional viral vector vaccines, new generation mRNA vaccines, BNT152b2 (Comirnaty) and mRNA-1273 (Spikevax), have been developed respectively by Pfizer/BioNTech and Moderna. These vaccines act on immune cells to induce an immune response with the production of specific antibodies against Spike protein of SARS-CoV-2, and to stimulate the differentiation of T and B memory cells. The objective of this review is to provide a detailed picture of the validity of these new vaccines and the safety of vaccination. Not only was the immunogenic effect of mRNA vaccines evaluated, but also the psychosocial impact they had on the population. The data collected show that this type of vaccine can also be an excellent candidate for future treatment and eradication of possible new pathologies with viral and non-viral etiology.
Keywords: Comirnaty; Immunity; SARS-CoV-2; Spikevax; Vaccination.